Citations

Clear

3138 citation(s) found for "Smith, AM".

Use of plasma late on cardiopulmonary bypass in patients undergoing left ventricular assist device implantation
Nelson, James A. , Soto, Juan C. Diaz , Stulak, John M., Schulte, Phillip J. , Weister, Timothy J. , Mauermann, William J., Diaz Soto, Juan C, Smith, Mark M , Nelson, James A. , Warner, Matthew A. , Smith, Mark M.

Mayo Clinic

Artificial Organs | August 17, 2021 | Volume: 46 | Issue: 3 | Pages: 491-500

10.1111/aor.14052 | PMID 34403155 Get It

AbstractCoagulopathy is common during left ventricular assist device (LVAD) implantation, treatment of which can be challenging given the often‐limited ability for the right ventricle to accommodate volume transfusion after device initiation with 20% to 40% of patients developing right ventricular failure (RVF). Transfusion of plasma late on cardiopulmonary bypass (CPB) combined with ultrafiltration may replace clotting factors while reducing volume administration. We compared outcomes in patients undergoing LVAD implantation receiving plasma on CPB and ultrafiltration with traditional transfusion practices. Co‐primary outcomes needed for blood product transfusion in the first 6 and 24 hours after CPB. Secondary outcomes included metrics of morbidity and mortality. 396 patients were analyzed (59 plasma on CPB). Patients receiving plasma on CPB had a greater volume of blood products transfused (3764 vs. 2741 mL first 6 hours; 6059 vs. 4305 mL first 24 hours) in unadjusted analysis. In adjusted analysis, plasma transfusion on CPB with ultrafiltration had no significant effect on the primary outcomes of blood products given in the first 6 hours (estimated effect size 982 [−428, 2392] mL, P = .17) and 24 hours (estimated effect size 1076 [−904, 3057] mL, P = .29). Patients receiving plasma on CPB were more likely on either vasopressors or inotropes at 24 hours after ICU admission (P = .01), however, indices of coagulopathy and RVF were similar between groups. While prospective studies would be necessary to definitively evaluate the clinical utility of this strategy, no signal for benefit was observed suggesting plasma should not be used for this purpose.
Association Between Transtibial Meniscus Root Repair and Rate of Meniscal Healing and Extrusion on Postoperative Magnetic Resonance Imaging: A Prospective Multicenter Study
Krych, Aaron J. , Nauert, Richard F. , Song, Bryant M. , Cook, Corey S., Johnson, Adam C. , Smith, Patrick A. , Krych, Aaron J , Stuart, Michael J.

Mayo Clinic

Orthopaedic Journal of Sports Medicine | August 16, 2021 | Volume: 9 | Issue: 8 | Pages: No page available

10.1177/23259671211023774 | PMID 34423058 Get It

Background: Prospective studies evaluating second-look imaging of meniscus root repair using a transtibial pull-out technique are limited; therefore, optimal surgical indications and the technique for meniscus root repair remain uncertain. Hypothesis: It was hypothesized that there would be a high rate of healing, improvement in meniscal extrusion, and prevention of articular cartilage degeneration and subchondral bone abnormalities after meniscus root repair. Study Design: Case series; Level of evidence, 4. Methods: Consecutive patients undergoing transtibial root repair were prospectively enrolled at 2 orthopaedic centers between March 2017 and January 2019. Pre- and postoperative magnetic resonance imaging (MRI) scans were reviewed by a musculoskeletal radiologist in a blinded fashion for meniscal healing, quantification of extrusion, articular cartilage grade, subchondral bone changes, and coronary/meniscotibial ligament abnormalities. Given persistent extrusion observed on postoperative MRI scans, an additional 10 patients gave consent and were enrolled for immediate (before weightbearing) postoperative MRI scans. Results: A total of 45 patients (16 male, 29 female; mean ± standard deviation age, 42.3 ± 12.9 years; body mass index, 31.6) were prospectively enrolled in the study; there were 47 meniscus root repairs: 29 medial and 18 lateral (2 with both). Postoperative MRI was obtained at an average of 6.3 months (range, 5.1-8 months); 98% of meniscal repairs had evidence of healing. Mean extrusion increased significantly, from 1.9 ± 1.5 mm preoperatively to 2.6 ± 1.4 mm postoperatively ( P = .03). There was no significant progression of chondromalacia grade, subchondral edema, insufficiency fracture, subchondral cysts, or subchondral collapse. In the additional 10-patient cohort, the mean preoperative extrusion (1.6 ± 1.2 mm) was not significantly different from that immediately postoperatively (2.0 ± 1.0 mm; P = .23). Conclusion: Prospective MRI analysis of transtibial meniscus root repair confirmed a high rate of meniscal healing and no observable progression of cartilage degeneration or subchondral bone abnormalities at the short-term follow-up. However, meniscal extrusion worsened in the first 6 months after surgery. Registration: NCT03037242 ( ClinicalTrials.gov identifier).
Diagnostic Accuracy of Endobronchial Optical Coherence Tomography for the Microscopic Diagnosis of Usual Interstitial Pneumonia
Nandy, Sreyankar , Raphaely, Rebecca A., Muniappan, Ashok, Shih, Angela, Roop, Benjamin W., Sharma, Amita, Keyes, Colleen M., Colby, Thomas V., Auchincloss, Hugh G., Gaissert, Henning A., Lanuti, Michael, Morse, Christopher R., Ott, Harald C., Wain, John C., Wright, Cameron D., Garcia-Moliner, Maria L., Smith, Maxwell L., VanderLaan, Paul A., Berigei, Sarita R., Mino-Kenudson, Mari, Horick, Nora K., Liang, Lloyd L., Davies, Diane L., Szabari, Margit V., Caravan, Peter, Medoff, Benjamin D., Tager, Andrew M., Suter, Melissa J., Hariri, Lida P., Horick, Nora , Liang, Lloyd L. , VanderLaan, Paul A. , Shih, Angela , Nandy, Sreyankar , Raphaely, Rebecca A., Muniappan, Ashok, Roop, Benjamin W., Sharma, Amita, Keyes, Colleen M., Colby, Thomas V., Auchincloss, Hugh G., Gaissert, Henning A., Lanuti, Michael, Morse, Christopher R., Ott, Harald C., Wain, John C., Wright, Cameron D., Garcia-Moliner, Maria L., Smith, Maxwell L., Berigei, Sarita R., Mino-Kenudson, Mari, Liang, Lloyd L., Davies, Diane L., Szabari, Margit V., Caravan, Peter, Medoff, Benjamin D., Tager, Andrew M., Suter, Melissa J., Hariri, Lida P., Shih, Angela , Horick, Nora

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | August 10, 2021 | Volume: 204 | Issue: 10 | Pages: 1164-1179

10.1164/rccm.202104-0847oc | PMID 34375171 Get It

Abstract Rationale Early, accurate diagnosis of interstitial lung disease (ILD) informs prognosis and therapy, especially in idiopathic pulmonary fibrosis (IPF). Current diagnostic methods are imperfect. High-resolution computed tomography has limited resolution, and surgical lung biopsy (SLB) carries risks of morbidity and mortality. Endobronchial optical coherence tomography (EB-OCT) is a low-risk, bronchoscope-compatible modality that images large lung volumes in vivo with microscopic resolution, including subpleural lung, and has the potential to improve the diagnostic accuracy of bronchoscopy for ILD diagnosis. Objectives We performed a prospective diagnostic accuracy study of EB-OCT in patients with ILD with a low-confidence diagnosis undergoing SLB. The primary endpoints were EB-OCT sensitivity/specificity for diagnosis of the histopathologic pattern of usual interstitial pneumonia (UIP) and clinical IPF. The secondary endpoint was agreement between EB-OCT and SLB for diagnosis of the ILD fibrosis pattern. Methods EB-OCT was performed immediately before SLB. The resulting EB-OCT images and histopathology were interpreted by blinded, independent pathologists. Clinical diagnosis was obtained from the treating pulmonologists after SLB, blinded to EB-OCT. Measurements and Main Results We enrolled 31 patients, and 4 were excluded because of inconclusive histopathology or lack of EB-OCT data. Twenty-seven patients were included in the analysis (16 men, average age: 65.0 yr): 12 were diagnosed with UIP and 15 with non-UIP ILD. Average FVC and Dl CO were 75.3% (SD, 18.5) and 53.5% (SD, 16.4), respectively. Sensitivity and specificity of EB-OCT was 100% (95% confidence interval, 75.8–100.0%) and 100% (79.6–100%), respectively, for both histopathologic UIP and clinical diagnosis of IPF. There was high agreement between EB-OCT and histopathology for diagnosis of ILD fibrosis pattern (weighted κ: 0.87 [0.72–1.0]). Conclusions EB-OCT is a safe, accurate method for microscopic ILD diagnosis, as a complement to high-resolution computed tomography and an alternative to SLB.
PaTH Forward: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of TransCon PTH in Adult Hypoparathyroidism
Khan, Aliya , Rubin, Mishaela R. , Vokes, Tamara , Ahmed, Intekhab, Hofbauer, Lorenz C. , Marcocci, Claudio , Palermo, Andrea , Eriksen, Erik Fink , Brod, Meryl , Markova, Denka, Pihl, Susanne, Mourya, Sanchita, Karpf, David, Shu, Aimee D , Clarke, Bart, Marcocci, Claudio , Palermo, Andrea , Shu, Aimee D , Hofbauer, Lorenz C , Rejnmark, Lars , Schwarz, Peter , Clarke, B.L. , Pagotto, Uberto , Smith, Alden Raymond

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | August 4, 2021 | Volume: 107 | Issue: 1 | Pages: e372-e385

10.1210/clinem/dgab577 | PMID 34347093 Get It

Abstract Context Hypoparathyroidism is characterized by insufficient levels of parathyroid hormone (PTH). TransCon PTH is an investigational long-acting prodrug of PTH(1-34) for the treatment of hypoparathyroidism. Objective This work aimed to investigate the safety, tolerability, and efficacy of daily TransCon PTH in adults with hypoparathyroidism. Methods This phase 2, randomized, double-blind, placebo-controlled 4-week trial with open-label extension enrolled 59 individuals with hypoparathyroidism. Interventions included TransCon PTH 15, 18, or 21 µg PTH(1-34)/day or placebo for 4 weeks, followed by a 22-week extension during which TransCon PTH dose was titrated (6-60 µg PTH[1-34]/day). Results By Week 26, 91% of participants treated with TransCon PTH achieved independence from standard of care (SoC, defined as active vitamin D = 0 μg/day and calcium [Ca] ≤ 500 mg/day). Mean 24-hour urine Ca (uCa) decreased from a baseline mean of 415 mg/24h to 178 mg/24h by Week 26 (n = 44) while normal serum Ca (sCa) was maintained and serum phosphate and serum calcium-phosphate product fell within the normal range. By Week 26, mean scores on the generic 36-Item Short Form Health Survey domains increased from below normal at baseline to within the normal range. The Hypoparathyroidism Patient Experience Scale symptom and impact scores improved through 26 weeks. TransCon PTH was well tolerated with no treatment-related serious or severe adverse events. Conclusion TransCon PTH enabled independence from oral active vitamin D and reduced Ca supplements (≤ 500 mg/day) for most participants, achieving normal sCa, serum phosphate, uCa, serum calcium-phosphate product, and demonstrating improved health-related quality of life. These results support TransCon PTH as a potential hormone replacement therapy for adults with hypoparathyroidism.
Diagnostic Imaging of A2 Pulley Injuries: A Review of the Literature
Berrigan, William A. , White, William D. , Cipriano, Kevin , Wickstrom, Jordan , Smith, Jay , Hager, Nelson, White, William

Mayo Clinic

Journal of Ultrasound in Medicine | August 3, 2021 | Volume: 41 | Issue: 5 | Pages: 1047-1059

10.1002/jum.15796 | PMID 34342037 Get It

Injury to the A2 pulley is caused by high eccentric forces on the flexor‐tendon–pulley system. Accurate diagnosis is necessary to identify the most appropriate treatment options. This review summarizes the literature with respect to using ultrasound (US) to diagnose A2 pulley injuries, compares ultrasound to magnetic resonance imaging and computed tomography, and identifies current knowledge gaps. The results suggest that US should be used as the primary imaging modality given high accuracy, relatively low cost, ease of access, and dynamic imaging capabilities. Manual resistance is beneficial to accentuate bowstringing, but further research is needed to determine best positioning for evaluation.
Fimepinostat (CUDC‐907) in patients with relapsed/refractory diffuse large B cell and high‐grade B‐cell lymphoma: report of a phase 2 trial and exploratory biomarker analyses
Landsburg, Daniel J. , Ramchandren, Radhakrishnan , Batlevi, Connie Lee , Iyer, Swaminathan P. , Kelly, Kevin R. , Micallef, Ivana N. , Smith, Sonali M. , Stevens, Don A., Alvarez, Mariano J. , Shen, Yao , Bosker, Gideon, Parker, Jefferson, Soikes, Raul, Martinez, Elizabeth , Roemeling, Reinhard von, Martell, Robert E., Oki, Yasuhiro , Landsburg, Daniel J , Barta, Stefan K , Califano, Andrea , Parker, Jefferson

Mayo Clinic

British Journal of Haematology | August 3, 2021 | Volume: 195 | Issue: 2 | Pages: 201-209

10.1111/bjh.17730 | PMID 34341990 Get It

SummaryFimepinostat (CUDC‐907), a first‐in‐class oral small‐molecule inhibitor of histone deacetylase and phosphatidylinositol 3‐kinase, demonstrated efficacy in a phase 1 study of patients with relapsed/refractory (R/R) diffuse large and high‐grade B‐cell lymphomas (DLBCL/HGBL), particularly those with increased MYC protein expression and/orMYCgene rearrangement/copy number gain (MYC‐altered disease). Therefore, a phase 2 study of fimepinostat was conducted in this patient population with 66 eligible patients treated. The primary end‐point of overall response (OR) rate for patients with MYC‐IHC ≥40% (n = 46) was 15%. Subsequently, exploratory pooled analyses were performed including patients treated on both the phase 1 and 2 studies based upon the presence of MYC‐altered disease as well as a biomarker identified by Virtual Inference of Protein activity by Enriched Regulon analysis (VIPER). For these patients with MYC‐altered disease (n = 63), the overall response (OR) rate was 22% with seven responding patients remaining on treatment for approximately two years or longer, and VIPER yielded a three‐protein biomarker classification with positive and negative predictive values of ≥85%. Prolonged durations of response were achieved by patients with MYC‐altered R/R DLBCL/HGBL treated with single‐agent fimepinostat. Combination therapies and/or biomarker‐based patient selection strategies may lead to higher response rates in future clinical trials.
A systematic review and gap analysis of frailty and oral health characteristics in older adults: A call for clinical translation
Slashcheva, Lyubov , Karjalahti, Erika, Hassett, Leslie C. , Smith, Barbara J. , Slashcheva, Lyubov D , Hassett, Leslie C , Smith, Barbara, Chamberlain, Alanna M.

Mayo Clinic

Gerodontology | July 31, 2021 | Volume: 38 | Issue: 4 | Pages: 338-350

10.1111/ger.12577 | PMID 34331353 Get It

AbstractObjectiveThis systematic review updates the evidence for association between oral health characteristics and frailty status, identifying gaps in translational dental research and application of frailty assessment into clinical practice.BackgroundClinicians have little guidance on stage‐appropriate dental treatment for medically complex older adults. Oral health characteristics have been associated with frailty status, determined through validated assessment tools representing a concise measure of health. Translation of frailty assessment into dental practice has not been the focus of previous reviews.MethodsUtilising the PRISMA framework for systematic reviews, a comprehensive database search identified articles describing the association of interest. Those included were cross‐sectional or longitudinal, in English, included participants aged 50 years or older, used validated frailty assessments and measured clinically relevant oral health outcomes. From 835 screened articles, 26 full‐text articles were eligible for quality appraisal and synthesis.ResultsFrailty prevalence ranged from 8.5% to 66.0%. Most studies utilised the Fried frailty criteria. Qualitative synthesis of 17 cross‐sectional and nine longitudinal studies demonstrated significant covariate‐adjusted association between frailty status and number of teeth, chewing ability, prosthetic characteristics, dental caries, periodontitis, dental utilisation and oral health‐related quality of life factors. Variability in findings reflected study sample diversity based on country of study origin, age at recruitment, sample size, frailty assessment type, use of clinical versus self‐reported outcome measures and differences in statistical analysis.ConclusionDespite robust evidence of association with oral health characteristics, frailty assessment has yet to be sufficiently applied to translational dental research and clinical practice.
Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor–Negative: ASCO Guideline Update
Moy, Beverly, Rumble, R. Bryan, Come, Steven E. , Davidson, Nancy E., Leo, Angelo Di , Gralow, Julie R. , Hortobágyi, Gabriel N. , Yee, Douglas , Smith, Ian E., Chávez‐MacGregor, Mariana , Nanda, Rita , McArthur, Heather L. , Reeder‐Hayes, Katherine E. , Ruddy, Kathryn J. , Unger, Paul S. , Vinayak, Shaveta, Irvin, William J., Armaghani, Avan, Danso, Michael A., Dickson, Natalie R. , Turner, Sophie S., Perkins, Cheryl L., Di Leo, Angelo , Spring, Laura , Reeder-Hayes, Katherine , Ruddy, Kathryn J , Unger, Paul S , Dickson, Natalie , Carey, Lisa A , Come, Steven , Hortobagyi, Gabriel N , Gralow, Julie R , Yee, Douglas , Chavez-MacGregor, Mariana , Moy, Beverly, Rumble, R. Bryan, Davidson, Nancy E., Smith, Ian E., Nanda, Rita , McArthur, Heather , Vinayak, Shaveta, Irvin, William J., Armaghani, Avan, Danso, Michael A., Turner, Sophie S., Perkins, Cheryl L.

Mayo Clinic

Journal of Clinical Oncology | July 29, 2021 | Volume: 39 | Issue: 35 | Pages: 3938-3958

10.1200/jco.21.01374 | PMID 34324366 Get It

PURPOSE This guideline updates recommendations of the ASCO guideline on chemotherapy and targeted therapy for patients with human epidermal growth factor receptor 2–negative metastatic breast cancer (MBC) that is either endocrine-pretreated or hormone receptor (HR)–negative. METHODS An Expert Panel conducted a targeted systematic literature review guided by a signals approach to identify new, potentially practice-changing data that might translate into revised guideline recommendations. RESULTS The Expert Panel reviewed abstracts from the literature review and retained 14 articles. RECOMMENDATIONS Patients with triple-negative, programmed cell death ligand-1–positive MBC may be offered the addition of immune checkpoint inhibitor to chemotherapy as first-line therapy. Patients with triple-negative, programmed cell death ligand-1–negative MBC should be offered single-agent chemotherapy rather than combination chemotherapy as first-line treatment, although combination regimens may be offered for life-threatening disease. Patients with triple-negative MBC who have received at least two prior therapies for MBC should be offered treatment with sacituzumab govitecan. Patients with triple-negative MBC with germline BRCA mutations previously treated with chemotherapy may be offered a poly (ADP-ribose) polymerase inhibitor rather than chemotherapy. Patients with HR-positive human epidermal growth factor receptor 2–negative MBC for whom chemotherapy is being considered should be offered single–agent chemotherapy rather than combination chemotherapy, although combination regimens may be offered for highly symptomatic or life-threatening disease. Patients with HR-positive MBC with disease progression on an endocrine agent may be offered treatment with either endocrine therapy with or without targeted therapy or single-agent chemotherapy. Patients with HR-positive MBC with germline BRCA mutations no longer benefiting from endocrine therapy may be offered a poly (ADP-ribose) polymerase inhibitor rather than chemotherapy. No recommendation regarding when a patient's care should be transitioned to hospice or best supportive care alone is possible. Additional information is available at www.asco.org/breast-cancer-guidelines .
Effects of Social Determinants of Health Care on Pediatric Thyroid Cancer Outcomes in the United States
Gruszczynski, Nelson , Meister, Kara D. , Balakrishnan, Karthik , Low, Christopher M. , Meister, Kara D , Balakrishnan, Karthik , Choby, Garret , Smith, Byron H.

Mayo Clinic

Otolaryngology–Head and Neck Surgery | July 27, 2021 | Volume: 166 | Issue: 6 | Pages: 1045-1054

10.1177/01945998211032901 | PMID 34311618 Get It

ObjectiveTo identify social determinants of health care that are associated with poorer pediatric well‐differentiated thyroid cancer (WDTC) outcomes and increased stage at presentation.Study DesignUsing the SEER database (Surveillance, Epidemiology, and End Results), we retrospectively gathered data on pediatric WDTC across the United States between 1973 and 2015.SettingAll patients between 0 and 19 years old with a diagnosis of WDTC were included.MethodsPatient variables were analyzed for relationships to AJCC stage at presentation (American Joint Committee on Cancer), overall survival, and disease‐specific survival.ResultsAmong 3913 patients with pediatric thyroid cancer, 3185 were female (81.4%), 3366 had papillary thyroid cancer (85.3%), and 367 had follicular thyroid cancer (9.4%). Two‐ and 5‐year overall and disease‐specific survival approached 100%. However, when outcomes were analyzed by specific populations, male sex, non‐Caucasian race, poverty, and language isolation were linked to worse overall survival. Male sex and poverty were associated with poorer disease‐specific survival. Regarding overall AJCC stage at presentation, male sex and Black race were related to higher overall presenting AJCC stage. Later AJCC T stage at presentation was seen in male, Hispanic, Asian, and Black patients. There were no variables significantly related to following through with recommended surgery.ConclusionPediatric WDTC continues to carry an excellent prognosis in the United States. However, when we consider specific populations, the social determinants of health care affect survival and disease burden at presentation: male sex, poverty, language isolation, and race affected survival and/or AJCC stage at presentation in pediatric WDTC.
Computerized Cognitive Training (CCT) versus Yoga Impact on 12 Month Post Intervention Cognitive Outcome in Individuals with Mild Cognitive Impairment
Phatak, Vaishali , Smith, Glenn E. , Shandera‐Ochsner, Anne L., Dean, P.M. , Ball, Colleen T. , Gutierrez, Gianna, Chandler, Melanie , Locke, Dona, Shandera-Ochsner, Anne, Chandler, Melanie J, Locke, Dona E.C. , Dean, Pamela M.

Mayo Clinic

Brain Sciences | July 27, 2021 | Volume: 11 | Issue: 8 | Pages: 988

10.3390/brainsci11080988 | PMID 34439607 Get It

There is currently limited and mixed evidence for the cognitive benefits of Computerized Cognitive Training (CCT) and yoga in persons with Mild Cognitive Impairment (pwMCI). The objective of this study was to investigate the benefit of computerized cognitive training (CCT) vs. physical (yoga) intervention on cognitive abilities. Participants in this study were part of the larger Mayo Clinic’s Healthy Action to Benefit Independence and Thinking (HABIT) program comparative effectiveness trial. The HABIT program is designed for pwMCI and their care partner and consists of five behavioral interventions: CCT, Memory Support System-Calendar (MSS-Calendar), wellness education, support groups, and yoga. The subtractive study design randomly withheld one of the interventions for a total of five study arms. Longitudinal mixed-effects regression models were used to investigate the hypothesis that CCT and yoga has a greater positive impact on psychomotor and basic attention abilities at 12 months post-intervention as compared to the other HABIT interventions. Findings showed CCT had a positive impact compared to yoga on the Cogstate psychomotor/attention composite at 12 months post-intervention (ES = 0.54; unadjusted p value = 0.007, adjusted p value = 0.021). The impact of yoga or combining CCT with yoga did not show statistically significant improvement. Continued CCT practice at home showed further benefit on psychomotor/attention at 12 months post-intervention. There was no significant benefit of CCT or yoga on Cogstate learning/working memory composite.